|Tested species reactivity||Human|
|Published species reactivity||Not Applicable|
|Host / Isotype||Mouse / IgG1, kappa|
|Storage buffer||PBS, pH 7.4, with 4mg/ml BSA, 40mg/ml glycerol|
|Contains||0.1% Proclin 300|
|Storage Conditions||4° C|
|Antibody Form||Whole Antibody|
|Tested Applications||Dilution *|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
Anti-Human secondary antibodies are affinity-purified antibodies with well-characterized specificity for human immunoglobulins and are useful in the detection, sorting or purification of its specified target. Secondary antibodies offer increased versatility enabling users to use many detection systems (e.g. HRP, AP, fluorescence). They can also provide greater sensitivity through signal amplification as multiple secondary antibodies can bind to a single primary antibody. Most commonly, secondary antibodies are generated by immunizing the host animal with a pooled population of immunoglobulins from the target species and can be further purified and modified (i.e. immunoaffinity chromatography, antibody fragmentation, label conjugation, etc.) to generate highly specific reagents.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
|Not Applicable||Not Cited||Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer.||Le Naour F,Misek DE,Krause MC,Deneux L,Giordano TJ,Scholl S,Hanash SM||Clinical cancer research : an official journal of the American Association for Cancer Research (7:3328)||2001|
Negligible adjuvant effect for antibody responses and frequent adverse events associated with IL-12 treatment in humans vaccinated with pneumococcal polysaccharide.
05-0520 was used in ELISA to test if co-administration of recombinant human IL-12 and 23-valent pneumococcal polysaccharide vaccine enhances the antibody response to this T cell-independent antigen.
|Hedlund J,Langer B,Konradsen HB,Ortqvist A||Vaccine (20:164)||2001|
|Not Applicable||Not Cited||
Immune response and lack of immune response to Plasmodium falciparum P126 antigen and its amino-terminal repeat in malaria-infected humans.
05-0520 was used in ELISA to assess the protective effects of immunization with the N-terminal region of the p126 protein.
|Banic DM,de Oliveira-Ferreira J,Pratt-Riccio LR,Conseil V,Gonçalves D,Fialho RR,Gras-Masse H,Daniel-Ribeiro CT,Camus D||The American journal of tropical medicine and hygiene (58:768)||1998|